Please login to the form below

Not currently logged in
Email:
Password:

Xofigo

This page shows the latest Xofigo news and features for those working in and with pharma, biotech and healthcare.

Pharma sales help Bayer escape the worst from a bumpy 2017

Pharma sales help Bayer escape the worst from a bumpy 2017

The two brands, along with cancer drugs Xofigo and Stivarga and pulmonary hypertension treatment Adempas, are seen by the company as its key growth brands.

Latest news

  • EMA clears Bayer's Stivarga for liver cancer EMA clears Bayer's Stivarga for liver cancer

    Stivarga is a key component among a new generation of pharma products - along with cancer drug Xofigo (radium-223 dichloride), anticoagulant Xarelto (rivaroxaban), ophthalmic therapy Eylea (aflibercept) and pulmonary arterial hypertension

  • Xarelto and Eylea continue to dominate Bayer's pharma sales Xarelto and Eylea continue to dominate Bayer's pharma sales

    The two products accounted for around 28% of Bayer's total pharma sales last year and are regarded as key growth products for the firm, along with its cancer drugs Xofigo ... Last year Xofigo (radium-223 dichloride) brought in 331m (up 29%) and Adempas

  • Xarelto leads the charge at Bayer Xarelto leads the charge at Bayer

    There were also gains for Eylea (aflibercept) for age-related macular degeneration (AMD) as well as prostate cancer drug Xofigo (radium Ra 223 dichloride) and Adempas (riociguat) for pulmonary artery hypertension.

  • Japanese approvals for GSK, AZ and Bayer Japanese approvals for GSK, AZ and Bayer

    Japanese approvals for GSK, AZ and Bayer. MHLW gives Nucala, Tagrisso and Xofigo the green light. ... Bayer has said it expects 50%-plus sales growth for Xofigo this year.

  • Price cut keeps Kadcyla on CDF Price cut keeps Kadcyla on CDF

    Bayer's Xofigo (radium-223 dichloride) for castration-resistant prostate cancer with bone metastases remains under appeal.

More from news
Approximately 10 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Pharma deals during June 2014 Pharma deals during June 2014

    Bayer paid 50m ($68m) upfront payment with further milestones in return for global rights which should complement Xofigo (from the acquisition of Algeta).

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    Hyperlipidemia. 2, 600. Algeta / Bayer. Acquisition. Buys out deal for Xofigo radiotherapeutic for.

  • Pharma deals during November 2013 Pharma deals during November 2013

    This takeover was an obvious tactic bringing in the key the asset, Xofigo which has been under joint development since 2009. ... Peak sales for Xofigo are expected to reach $1.5bn plus further upside from other indications in development.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics